Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 239-246 , July 2009

Hazards of hepatitis at the Hajj

  • Shafquat M. Rafiq

      Affiliations

    • Unit of Gastroenterology, Department of Medicine, Epsom and St Helier University Hospitals NHS Trust, Dorking Road, KT18 7EG, Surrey, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0) 1372 735119; fax: +44 (0) 1372 735955.
    • ,
  • Harunor Rashid

      Affiliations

    • Academic Unit of Child Health, Barts and the London Queen Mary's School of Medicine and Dentistry, London, UK
    • ,
  • Elizabeth Haworth

      Affiliations

    • Health Protection Agency, South East, London, UK
    • ,
  • Robert Booy

      Affiliations

    • Academic Unit of Child Health, Barts and the London Queen Mary's School of Medicine and Dentistry, London, UK
    • National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and The University of Sydney, New South Wales, Australia

Received 25 August 2008 ,Accepted 8 September 2008.

References 

  1. Shafi S, Memish ZA, Gatrad AR, Sheikh A. Hajj 2006: communicable disease and other health risks and current official guidance for pilgrims. Euro Surveill. 2005;10:E051215.2
  2. Memish ZA. Infection control in Saudi Arabia: meeting the challenge. Am J Infect Control. 2002;30:57–65
  3. Burckhardt JL. Travels in Arabia. London: Frank and Cass; 1829;
  4. Aguilera JF, Perrocheau A, Meffre C, Hahne S, the W135 Working Group . Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe. Emerg Infect Dis. 2002;8:761–767
  5. Ahmed QA, Arabi YM, Memish ZA. Health risks at Hajj. Lancet. 2006;367:1008–1015
  6. Winston R. The story of God. London: Bantam Press; 2005;
  7. Hanlon V. Days of the Hajj. CMAJ. 2000;163:1598–1599
  8. Gatrad AR, Sheikh A. Hajj: journey of a lifetime. BMJ. 2005;330:133–137
  9. Zuckerman JN, Steffen R. Risks of hepatitis B in travelers as compared to immunization status. J Travel Med. 2000;7:170–174
  10. Khuroo MS. Viral hepatitis in international travellers: risks and prevention. Int J Antimicrob Agents. 2003;21:143–152
  11. World Health Organization . Hepatitis A. Avaialable from: http://www.who.int/csr/disease/hepatitis/HepatitisA_whocdscsredc2000_7.pdf[accessed 25.08.08]
  12. World Health Organization . Hepatitis A vaccines: WHO position paper. Wkly Epidemiol Rec. 2000;75:38–42
  13. Public Health Agency of Canada . Hepatitis A. Avaialble from: http://www.phac-aspc.gc.ca/tmp-pmv/info/hepa_e.html[accessed 25.08.08]
  14. Heymann DL. Control of communicable disease manual. 18th ed.. Washington DC: American Public Health Association; 2004;
  15. Alrabeh AM, El-Bushra HE, Al-Sayed MO, et al. Behavioral risk factors for disease during Hajj: the second survey. Saudi Epidemiol Bull. 1998;5:19–20
  16. Memish ZA, Venkatesh S, Ahmed QA. Travel epidemiology: the Saudi perspective. Int J Antimicrob Agents. 2003;21:96–101
  17. Brundage SC, Fitzpatrick AN. Hepatitis A. Am Fam Physician. 2006;73:2162–2168
  18. Anonymous . Supplementary statement on hepatitis A vaccine (ACS-4). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Can Commun Dis Rep. 2000;26:12–18
  19. Nothdurft HD. Hepatitis A vaccines. Expert Rev Vaccines. 2008;7:535–545
  20. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171:S44–S49
  21. Advisory Committee on Immunization Practices (ACIP) , Fiore AE, Walsey A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1–23
  22. Lee SD, Chan C, Yu MI, Wang YJ, et al. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. Am J Gastroenterol. 1996;91:1360–1362
  23. Bianco E, De Masi S, Mele A, Jefferson T. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Dig Liver Dis. 2004;36:834–842
  24. Sonder GJB, van Steenbergen JE, Bovee LPMJ, et al. Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996–2000: an evaluation of current prevention policy. Am J Public Health. 2004;94:1620–1626
  25. Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J. 2007;26:116–122
  26. Alavian SM, Keyvani H, Rezai M, et al. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006;12:5211–5213
  27. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat. 2007;14(Suppl. 1):11–15
  28. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology. 1995;38:24–34
  29. World Health Organization . Hepatitis B. Available from: http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf[accessed 25.08.08]
  30. Kowdley KV. The cost of managing chronic hepatitis B infection: a global perspective. J Clin Gastroenterol. 2004;38:S132–S133
  31. Jacob A, Kowdley KV. Epidemiology of hepatitis B – clinical implications. MedGenMed. 2006;8:13
  32. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–S9
  33. Saravanan S, Velu V, Kumarasamy N, et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol. 2007;13:5015–5020
  34. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101–1108
  35. Al-Faleh FZ. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. Ann Saudi Med. 2003;23:367–371
  36. Ibarra VH. The changing epidemiology of viral hepatitis in Chile. Rev Med Chile. 2007;135:229–239
  37. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measure. J Viral Hepat. 2004;11:97–107
  38. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000
  39. El Beltagy KE, Al Balawi IA, Almuneef M, Memish ZA. Prevalence of hepatitis B virus markers among blood donors in a tertiary hospital in Tabuk, northwestern Saudi Arabia. Int J Infect Dis. 2008;12:495–499
  40. Al-Salama A, El-Bushra H. Head shaving practices of barbers and pilgrims to Makkah,1998. Saudi Epidemiol Bull. 1998;5:17–18
  41. Gatrad AR, Sheikh A. Hajj and risk of blood borne infections. Arch Dis Child. 2001;84:375
  42. Rashid H, Shafi S. Blood borne hepatitis at Hajj. Hep Mon. 2006;6:87–88
  43. Turkistani A, Al-Rumikhan A, Mustafa T. Blood-borne diseases among barbers during Hajj, 1419 H (1999). Saudi Epidemiol Bull. 2000;7:1–2
  44. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–125
  45. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Marglois HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–1339
  46. Keystone JS. Travel-related hepatitis B: risk factors and prevention using an accelerated vaccination schedule. Am J Med. 2005;118:63S–68S
  47. Zuckerman JN, Van Damme P, Van Herck K, Loscher T. Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Med Infect Dis. 2003;1:219–226
  48. Hsu CE, Liu LC, Juon HS, et al. Reducing liver cancer disparities: a community-based hepatitis-B prevention program for Asian–American communities. J Natl Med Assoc. 2007;99:900–907
  49. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des. 2008;14:1646–1654
  50. Osoba AO, Ibrahim M, Abdelaal MA, Al-Mowallad A, Al Shareef B, Hussain BA. Hepatitis C virus genotyping by polymerase chain reaction and DNA enzyme immunoassay among Saudi patients in the western province, Saudi Arabia. Ann Saudi Med. 2000;20:394–397
  51. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injecting drug users in Scotland. Hepatology. 2005;42:711–723
  52. Anonymous . EASL international consensus conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol. 1999;31:3–8
  53. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol. 2008;7:114–119
  54. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–2441
  55. Zein NN. Hepatitis C in children: recent advances. Curr Opin Pediatr. 2007;19:570–574
  56. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36:S93–S98
  57. Khan NA, Ishag AM, Ahmad MS, El-Sayed FM, Bachal ZA, Abbas TG. Pattern of medical diseases and determinants of prognosis of hospitalization during 2005 Muslim pilgrimage Hajj in a tertiary care hospital. Saudi Med J. 2006;27:1373–1380
  58. Mahaba H, el-Tayeb Ael-K, Elbaz H. The prevalence of antibodies to hepatitis C virus in Hail region, Saudi Arabia. Egypt Public Health Assoc. 1999;74:69–80
  59. Lock G, Dirscherl M, Obermeier F, et al. Hepatitis C – contamination of toothbrushes: myth or reality?. J Viral Hepat. 2006;13:571–573
  60. Gatrad AR, Aziz S. Risk factors for HIV/AIDS in Muslim communities. Divers Health Soc Care. 2004;1:65–69
  61. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther. 2008;13:3–8
  62. D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. R Soc Med. 2004;97:223–225
  63. Desbois D, Vaghefi P, Savary J, Dussaix E, Roque-Afonso AM. Sensitivity of a rapid immuno-chromatographic test for hepatitis C antibodies detection. J Clin Virol. 2008;41:129–133
  64. Taylor JM. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol. 2006;307:1–23
  65. Hadziyannis SJ. Decreasing prevalence of hepatitis D virus infection. J Gastroenterol Hepatol. 1997;12:745–746
  66. Huo TI, Wu JC, Lin RY, Sheng WY, Chang FY, Lee SD. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J Gastroenterol Hepatol. 1997;12:747–751
  67. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in south London. J Med Virol. 2008;80:277–282
  68. Flodgren E, Bengtsson S, Knutsson M, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. 2000;38:3311–3316
  69. Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc. 2006;105:869–881
  70. Krawczynski K, Kamili S, Aggarwal R. Global epidemiology and medical aspects of hepatitis E. Forum (Genova). 2001;11:166–179
  71. Zuckerman JN. Hepatitis E and the traveller. Travel Med Infect Dis. 2003;1:73–76
  72. Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 2008;28:1190–1199
  73. Khogali M. Epidemiology of heat illnesses during the Makkah pilgrimages in Saudi Arabia. Int J Epidemiol. 1983;12:267–273
  74. Arif M, Qattan I, al-Faleh F, Ramia S. Epidemiology of hepatitis E virus (HEV) infection in Saudi Arabia. Ann Trop Med Parasitol. 1994;88:163–168
  75. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895–903
  76. Charrel RN, Zaki AM, Attoui H, et al. Complete coding sequence of the alkhurma virus, a tick-borne flavivirus causing severe hemorrhagic fever in humans in Saudi Arabia. Biochem Biophys Res Commun. 2001;287:455–461
  77. Zaki AM. Isolation of a flavivirus related to the tick-borne encephalitis complex from human cases in Saudi Arabia. Trans R Soc Trop Med Hyg. 1997;91:179–181
  78. Charrel RN, Fagbo S, Moureau G, Alqahtani MH, Temmam S, de Lamballerie X. Alkhurma hemorrhagic fever virus in ornithodoros savignyi ticks. Emerg Infect Dis. 2007;13:153–155
  79. Charrel RN, Zaki AM, Fakeeh M, et al. Low diversity of alkhurma hemorrhagic fever virus, Saudi Arabia, 1994–1999. Emerg Infect Dis. 2005;11:683–688
  80. Madani TA, Al-Mazrou YY, Al-Jeffri MH, et al. Rift valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003;37:1084–1092
  81. Davies FG. Risk of a rift valley fever epidemic at the haj in Mecca, Saudi Arabia. Rev Sci Tech. 2006;25:137–147

PII: S1477-8939(08)00125-7

doi: 10.1016/j.tmaid.2008.09.008

Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 239-246 , July 2009

Article Tools

* Image Usage & Resolution